Annual report pursuant to Section 13 and 15(d)

Iloperidone Sublicense to Novartis Pharma AG (Details Textual)

v2.4.1.9
Iloperidone Sublicense to Novartis Pharma AG (Details Textual)
12 Months Ended
Dec. 31, 2014
Minimum [Member]  
Operating Leased Assets [Line Items]  
Percentage Of Next Slab Of Annual Sales For Calculating Net Royalty 8.00%ttnp_PercentageOfNextSlabOfAnnualSalesForCalculatingNetRoyalty
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
Maximum [Member]  
Operating Leased Assets [Line Items]  
Percentage Of Next Slab Of Annual Sales For Calculating Net Royalty 10.00%ttnp_PercentageOfNextSlabOfAnnualSalesForCalculatingNetRoyalty
/ us-gaap_RangeAxis
= us-gaap_MaximumMember